ProfileGDS5678 / 1456266_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 66% 64% 69% 63% 63% 67% 66% 64% 71% 68% 65% 63% 65% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.9761466
GSM967853U87-EV human glioblastoma xenograft - Control 23.8350664
GSM967854U87-EV human glioblastoma xenograft - Control 34.2648869
GSM967855U87-EV human glioblastoma xenograft - Control 43.7635663
GSM967856U87-EV human glioblastoma xenograft - Control 53.7354563
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.097167
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0760966
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.8589664
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.4897471
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.2167468
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8710165
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.724963
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9209465
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8209764